Linked Life Data

9756784

Source:http://linkedlifedata.com/resource/pubmed/id/9756784

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
1998-11-9
pubmed:abstractText
In this study, treatment efficacies of a nonionic surfactant vesicle formulation of sodium stibogluconate (SSG-NIV) and of several formulations of amphotericin B were compared in a murine model of visceral leishmaniasis. Treatment with multiple doses of AmBisome, Abelcet, and Amphocil (total dose, 12.5 mg of amphotericin B/kg of body weight) resulted in a significant suppression of parasite burdens in liver (P < 0.0005) and spleen (P < 0.0005) compared with those of controls, with Abelcet having the lowest activity. Only AmBisome and Amphocil gave significant suppression of parasites in bone marrow (compared to control values, P < 0.005). In the acute-infection model, single-dose treatments of SSG-NIV (296 mg of SbV/kg), SSG solution (296 mg of SbV/kg), or AmBisome (8 mg of amphotericin B/kg) were equally effective against liver parasites (compared to control values, P < 0.0005). SSG-NIV and AmBisome treatment also significantly suppressed parasites in bone marrow and spleen (P < 0.005), with SSG-NIV treatment being more suppressive (>98% suppression in all three sites). Free-SSG treatment failed to suppress spleen or bone marrow parasites. Infection status influenced treatment outcome. In the chronic-infection model, the AmBisome single-dose treatment was less effective in all three infection sites and the SSG-NIV single-dose treatment was less effective in the spleen. The results of this study suggest that the antileishmanial efficacy of SSG-NIV compares favorably with those of the novel amphotericin B formulations.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/9756784-2568434, http://linkedlifedata.com/resource/pubmed/commentcorrection/9756784-2899637, http://linkedlifedata.com/resource/pubmed/commentcorrection/9756784-606433, http://linkedlifedata.com/resource/pubmed/commentcorrection/9756784-7655816, http://linkedlifedata.com/resource/pubmed/commentcorrection/9756784-8394861, http://linkedlifedata.com/resource/pubmed/commentcorrection/9756784-8723469, http://linkedlifedata.com/resource/pubmed/commentcorrection/9756784-8944278, http://linkedlifedata.com/resource/pubmed/commentcorrection/9756784-9145744, http://linkedlifedata.com/resource/pubmed/commentcorrection/9756784-9333030, http://linkedlifedata.com/resource/pubmed/commentcorrection/9756784-9373770, http://linkedlifedata.com/resource/pubmed/commentcorrection/9756784-9559804
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0066-4804
pubmed:author
pubmed:issnType
Print
pubmed:volume
42
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2722-5
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1998
pubmed:articleTitle
Visceral leishmaniasis in the BALB/c mouse: a comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B.
pubmed:affiliation
Departments of Pharmaceutical Sciences, University of Strathclyde, Glasgow, United Kingdom.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't